News | March 17, 2008

Bristol-Myers Squibb Medical Imaging Renamed Lantheus Medical Imaging

March 18, 2008 – Today Bristol-Myers Squibb Medical Imaging introduced its new name by launching Lantheus Medical Imaging, marking the first time in the company’s 50-year history that it will operate as an independent company.

The launch builds on the momentum created by the acquisition of the business by Avista Capital Partners in January of this year. The Massachusetts-based company, acquired by Avista Capital Partners in January 2008, will continue to provide medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite (Technetium Tc99m Generator).

Lantheus Medical Imaging’s new President and CEO Don Kiepert said, “Lantheus Medical Imaging is well-positioned for growth with a market-leading product portfolio, promising pipeline and a world-class organization committed to the field of medical imaging. Our people are passionate about developing innovative, clinically meaningful diagnostic tools that enhance and improve patient care.”

Before joining Lantheus Medical Imaging, Kiepert was the founder and former Chairman, CEO and President of Point Therapeutics since 1996. Prior to that he was president and CEO of Chartwell Home Therapies, a home infusion services company, from 1989 to 1996. Kiepert also started and managed several health care companies and worked in various management positions at Baxter Travenol, Inc. Kiepert received his M.S. degree in clinical pharmacy from Purdue University.

For more information: www.lantheus.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Technical University of Munich, Munich Compact Light Source, MuCLS, angiography, contrast agents

(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.

News | Angiography| March 10, 2017
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients,...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init